Related references
Note: Only part of the references are listed.Safety and Tolerability of Dalcetrapib
Evan A. Stein et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Inhibition of cholesteryl ester transfer protein (CETP): Different in vitro characteristics of RO4607381/JTT-705 and torcetrapib (TOR)
E. J. Niesor et al.
ATHEROSCLEROSIS (2008)
Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
M. J. Forrest et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Guide to receptors and channels (GRAC), 3rd edition
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials
Menno Vergeer et al.
CIRCULATION (2008)
Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
Stephen J. Nicholls et al.
CIRCULATION (2008)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial
Michiel L. Bots et al.
LANCET (2007)
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia
John J. P. Kastelein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of torcetrapib on the progression of coronary atherosclerosis
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules
Xiayang Qiu et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action
RW Clark et al.
JOURNAL OF LIPID RESEARCH (2006)
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease
PJ Barter et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
The effects of quinapril and atorvastatin on artery structure and function in adult spontaneously hypertensive rats
LF Yang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production
MA Potenza et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with Pravastatin in type II dyslipidemia
JA Kuivenhoven et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Animal models of hypertension: An overview
LO Lerman et al.
JOURNAL OF LABORATORY AND CLINICAL MEDICINE (2005)
Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib
RW Clark et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Cholesteryl ester transfer protein - A novel target for raising HDL and inhibiting atherosclerosis
PJ Barter et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Vascular inflammation and the renin-angiotensin system
AR Brasier et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans - A randomized phase II dose-response study
GJ de Grooth et al.
CIRCULATION (2002)
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
H Okamoto et al.
NATURE (2000)
Share Paper
